Identifying Novel FGFR3 Inhibitors By XtalPi-Curated HTS Diversity Library

Blog details
2 min read
Share this:
Case Study: How XtalPi Used Diversity Library of 80K Compounds to Find Hits Targeting FGFR3 

Mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) are linked to various cancers, making it a critical target for therapeutic intervention. But targeting specific FGFR members individually is very challenging due to their structural similarities. Currently only pan-inhibitors are approved by the FDA.

In an effort to selectively target FGFR3, XtalPi sought to identify novel scaffolds using our curated high-throughput screening (HTS) diversity library.

Our Key Results:

  • Discovery of 15 potent hit compounds, each exhibiting biochemical potency with IC50 values below 10 μM.
  • Identified three hit series which possessed novel scaffolds that are distinct from those of known FGFR3 inhibitors, providing new avenues for selectively targeting the protein.

Your next success starts here

Recommended articles

Development of small molecule selective inhibitors with XFEP
Discovery of Novel Non-covalent GPX4 Potent Hits with XFEP
Discovery of Novel Leads Targeting a Highly Flexible Allosteric Site with XMolGen and XFEP
Extract 1500 structures and activity data within one hour